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Abstract 
Purpose: To investigate the protective effect of Rhodiola rosea L. extract (RRLE) against Alzheimer's 
disease in 3xTg-AD mice. 
Methods: The cognitive function of 3xTg-AD mice was assessed using Morris water maze test. The 
levels of amyloid beta deposits and NeuN in the hippocampus were evaluated by 
immunohistochemistry. Brain neurotrophic-derived factor (BDNF) and tyrosine kinase B (TrkB) 
expressions were examined by western blot analysis. 
Results: RRLE treatment significantly ameliorated learning and memory deficits in AD mice, as shown 
by increased time spent in the target zone during probe tests. The escape latency in animals treated 
with 400 mg/kg RRLE (20.5 ± 1.3 s) was significantly increased compared to the untreated mice (12.4 ± 
1.3 s, p < 0.01). In addition, RRLE significantly decreased Aβ deposits, increased NeuN-positive cells, 
and upregulated the expression of BDNF (1.4 ± 0.2, p < 0.05) and TrkB (1.1 ± 0.2, p < 0.05) in the mice. 
Conclusion: The findings suggest that RRLE treatment may be a useful strategy for treating memory 
impairment induced by several neurodegenerative diseases.  
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Alzheimer’s disease (AD) is the most common 
form of dementia in the elderly and accounts for 
between 50 and 75 % of all cases. By 2030 it is 
estimated that more than 65 million people will 
be living with dementia, with projections almost 
doubling every 20 years. AD is a progressive 
neurodegenerative disorder characterized, at 
least in part, by abnormal accumulation of β-
amyloid peptide (Aβ) in the brain [1]. The 
accumulated Aβ is believed to play an important 
role in the pathogenesis of AD [2].  Thus, Aβ 
continues to be an important target for prevention 
and treatment of AD [3]. 
 
Alzheimer's disease is the most common form of 
dementia relating to memory and cognitive 
decline. AD is a progressive neurodegenerative 
disease in which dementia symptoms gradually 
worsen over a number of years [4]. Classical 
biochemical hallmarks of AD include the 
accumulation of amyloid beta (Aβ) peptide 
oligomers and soluble hyperphosphorylated tau 
[5]. Brain-derived neurotrophic factor (BDNF) is a 
small dimeric protein, and BDNF acts through 
high affinity binding with its receptor, tyrosine 
kinase B (TrkB). BDNF modulates neuronal 
growth and survival, and BDNF is implicated in 
learning and memory processes; therefore, 
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dysfunction in BDNF is accompanied by 
cognitive deficits. In particular, BDNF is involved 
in the AD-related decline of neurogenesis, and 
levels of nerve growth factor are also diminished 
with AD [6].  
 
Medical treatment for AD patients is placing an 
increasing burden on physicians and families 
every year. Clinically, there are a variety of drugs 
available for AD, such as cholinesterase 
inhibitors, glutamate receptor antagonists, and 
free radical scavengers. However, these drugs 
do not closely target the pathogenesis of the 
disease and have numerous side effects [7]. 
Therefore, it is extremely important to elucidate 
the mechanism of AD pathophysiology to find a 
new drug for treatment. 
 
Rhodiola rosea L., has been used in China in the 
treatment of various disorders, including stress-
induced physiological changes, inflammation, 
hypertension, and cancer. Rhodiola rosea L. 
extract has been reported to have anti-oxidant 
[8], immunomodulatory [9], and anti-mutagenic 
activity [10]. In this study, we investigated to 
evaluate the neuroprotective effects of RRLE on 
learning and memory deficits in a triple-
transgenic mouse model of Alzheimer's disease 
(3xTg-AD), which expresses APPSwe, PS1M146V, 






The plant material, Rhodiola rosea L., were 
collected from Pingdingshan City, Henan 
Province in China in October 2015. Taxonomic 
identification of the plant was performed by 
Professor Gang Wang of Shandong University, in 
China. A voucher specimen (no. PRLE 
201605002) was deposited in College of 
Pharmacy, Shandong University, China for future 
reference.  
 
The herbal samples Rhodiola rosea L. was dried 
in an oven. RRLE was obtained by steeping the 
dried Rhodiola rosea L. in water at 60 oC three 
times, each for one hour before first drying in an 
oven and then freeze-drying the RRLE thus 
obtained. One gram powder was equivalent to 





Alzheimer's disease (3xTg-AD) mice carrying a 
mutant APP (KM670/671NL), a human mutant 
PS1 (M146V) knock-in, and tau (P301L) 
transgenes (B6;129-Psen1tm1Mpm Tg 
(APPSwe,tauP301L)1Lfa/J) were purchased 
from the animal research institute, Nanjing 
University (Nanjing, China). The non-transgenic 
littermates were used as wild type (WT) controls. 
All animals were kept in a pathogen-free 
environment on a 12 h light/dark cycle and had 
access to food and water ad libitum. 
 
Animal groups  
 
The mice were randomly divided into four groups 
as follows: (1) saline treated WT group (WT, n = 
8); (2) saline-treated 3xTg group (3xTg, n = 8); 
(3) 200 mg/kg RRLE-treated 3xTg group (3xTgþ 
+ RRLE 200, n = 8) and (4) 400 mg/kg RRLE-
treated 3xTg group (3xTgþ + RRLE 400, n = 8). 
Starting at 3 months of age, mice received PBS 
and RRLE once a week for 3 months until they 
were 6 months old. Drugs were dissolved in 
water, and administered using a 5-ml syringe 
with a 2-cm long gavage needle through the 
mouth to the mouth once daily for 3 weeks. The 
animal experiment was approved by the Animal 
Care and Use Committee of Shandong 
University (approval ref no. 20100405) and was 
carried out in compliance with the Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [12]. 
 
Water maze test 
 
A modified version of the water maze procedure 
described by Morris was used to test each 
mouse's cognitive function [13]. The water maze 
was a circular pool 0.9 m in diameter and 
constructed of fiberglass. Water in the pool was 
maintained at 22 ± 2 oC and mixed with 1 kg of 
powdered skim milk to make the water opaque. 
During testing in the water maze, a platform (6 
cm in diameter) was fixed 1 cm below the 
surface of the water at identical location within 
the pool. The pool was surrounded by differing 
extra-maze cues. All mice were subjected to four 
trials per day at intervals of 15 min for four 
consecutive days. The proportion of time spent 
searching for the platform in the training 
quadrant, i.e., the previous location of the 





At the end of the experiment, the mice were 
decapitated and the brains were rapidly removed 
and placed on ice. The hippocampus was quickly 
dissected by a scalpel and stored at -80 oC fridge 
until use. The hippocampal tissue was 
homogenized in PRO-PREPTM Protein 
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Extraction Solution (Shanghai Shengong, 
Shanghai, China). The homogenates were 
subsequently centrifuged at 12,000 g for 10 min 
at 4 oC, and the supernatants were collected for 
protein concentration determination using a 
protein assay (Bio-Rad, Hercules, CA, USA). 
Protein samples (30 μg) were separated on a 
sodium dodecyl sulfate-polyacryl-amide gel and 
transferred onto a nitrocellulose membrane. The 
membranes were incubated with 5 % skim milk in 
Tris-buffered saline containing 0.1 % Tween-20 
and then incubated overnight at 4 oC with the 
following primary antibodies: mouse β- actin 
antibody (1 : 1000; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), rabbit BDNF antibody (1 : 
500; Santa Cruz Biotechnology), and rabbit TrkB 
antibody (1 : 1000; Santa Cruz Biotechnology). 
Subsequently, membranes were incubated for 1 
h with secondary antibodies (1 : 2000; Cell 
Signaling), and detection was performed using 





Coronal sections of the hippocampus were 
examined from the rostral anteroposterior (- 2.1 
mm) to the anteroposterior (- 4.5 mm) direction, 
as defined by the bregma of the brain atlas. 
Images were obtained at 10 × magnification 
using the IMAGE PRO PLUS System (version 
4.0; Media Cybernetics, Silver Spring, MD, USA) 
on a computer attached to a light microscope 
(Zeiss Axioskop, Oberkochen, Germany), which 
interfaced with a chargecoupled device video 
camera (Kodak Mega Plus model 1.4 I). To 
determine the density of the Aβ-immunoreactive 
staining in the hippocampus, a square frame of 
500 × 500 μm2 was placed in the dorsal part of 
the hippocampus. A second square frame of 200 
× 200 μm2 was placed in the corpus callosum to 
measure the background. As previously 
described, variations in background illumination 
were controlled by subtracting the average 
background density of the corpus callosum from 
the average density of the hippocampus in each 




Data are presented as mean ± standard 
deviation (SD). Results were analyzed 
statistically by one-way ANOVA followed by 
Tukey’s multiple comparison using SPSS 16.0 
software for Windows. Differences were 





RRLE reverses spatial learning deficits at 6 
months of age in mice 
 
To examine spatial memory, the performance of 
animals in the probe trial was compared to the 
time animals spent swimming to the platform. All 
animals were examined by a retention test that 
involved removing the platform from the pool on 
the fourth trial day. From Table 1, the escape 
latency in animals treated with 400 mg/kg RRLE 
was significantly increased as compared to the 
3xTg-AD mice. 
 
Table 1: Effect of RRLE on behavior in a Morris water 
maze 
 
Group Number Escape latency(s) 
Control 8 23.6 ± 1.6 
3xTg 8 12.4 ± 1.3** 
RRLE-L 8 13.9 ± 0.9 
RRLE-H 8 20.5 ± 1.3## 
Escape latency was determined using the hidden 
platform test. Significance was determined by 
Student's t test; **p < 0.01, compared with the control 
group; ##p < 0.01, compared with the 3xTg group) 
 
3xTg-AD mice displayed severely impaired 
spatial cognition in the water maze test 
compared with the WT controls, and the 
administration of RRLE ameliorated these 
learning and memory deficits. 
 
Effect of RRLE on Aβ pathology in mice 
 
In 3xTg-AD mice, Aβ is present in the 
hippocampus by 6 months of age. Therefore, to 
investigate the link between neurogenesis and 
the development of AD pathology, we assessed 
the Aβ burden in brains from 3xTg-AD mice that 
began receiving RRLE treatments 3 month prior 
to 6 months of age. Aβ deposits in the CA1 
region of the hippocampus were significantly 
increased in 6-month-old 3xTg animals 
compared to the age-matched WT group (p < 
0.01). In the CA3 region of the hippocampus, Aβ 
deposits were significantly increased in the 3xTg 
group (p < 0.001) compared to the WT group (p 
< 0.01).  
 
Compared with the 3xTg group, Aβ deposits in 
the CA1 region were significantly decreased by 
RRLE 400 mg treatment (p < 0.05). In addition, 
compared with the 3xTg group, Aβ deposition in 
the CA3 was significantly decreased by RRLE 
200 mg treatment (p < 0.05). However, there 
were no significant differences between the 3xTg 
group and the 3xTgþ RRLE (400 mg/kg) (Table 
2). 
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Effect of RRLE on the expressions of BDNF 
and TrkB and in mice hippocampus 
 
The effect of RRLE treatment on the expression 
of hippocampal BDNF and TrkB in mice was 
determined. The results are shown in Table 3. 
The expression of hippocampal BDNF and TrkB 
of mice treatment with saline was significantly 
lower compared to that of WT mice (p < 0.05).It 
was also demonstrated that RRLE treatment 
significantly increased the expression of 
hippocampal BDNF and TrkB. These results 
show that the induction of AD reduced BDNF and 
TrkB expressions in the hippocampus, whereas, 
RRLE treatment enhanced BDNF and TrkB 





The present study demonstrated that RRLE 
increased spatial learning, memory abilities, and 
the expression of hippocampal BDNF and TrkB 
in 3xTg-AD mice. In the present study, we chose 
to use 3xTg-AD mice, a model derived from 
APPSwe, PS1M146V, and tauP301L transgenes. The 
3xTg-AD mice develop a progressive, age-
related neuropathological phenotype that 
includes plaque and tangle pathologies. Both of 
these hallmark lesions are mainly limited to the 
hippocampus, amygdala, and cerebral cortex – 
the brain structures most impacted by AD 
pathology [15].  
 
Cognitive impairment has been detected in 2-
month-old 3xTg-AD mice [16], and Aβ deposits in 
the hippocampus and cortex have been found in 
6-month-old 3xTg-AD mice [17-19]. These 
findings indicate that the pathological features 
that imitate AD in 3xTgAD mice remain stable. 
Classic symptoms of AD include problems with 
spatial learning and memory deficits. Our study 
demonstrated that treatment with RRLE resulted 
in a significant restoration of spatial learning and 
memory function in AD mice. These results 
suggest that RRLE treatment may be effective in 
ameliorating cognitive impairment caused by AD.  
 
Neuron-specific nuclear antigen (NeuN) is a 
neuronal-specific nuclear protein [20,21]. The 
expression of NeuN is observed in most neuronal 
cell types throughout the nervous system, with 
the exception of some neuronal populations that 
are NeuN-negative, but does not stain non-
neuronal cells [22]. NeuN is a soluble nuclear 
protein that is localized to the cell nucleus and in 
the neuronal cytoplasm of postmitotic neurons. 
Within the hippocampus, NeuN can be used as a 
marker of postmitotic cells and labels both 
“normal” postmitotic neurons and newly 
generated postmitoticneurons. BDNF plays 
pivotal roles in learning, memory, and neuronal 
plasticity. 
 
The levels of BDNF, and its main receptor TrkB, 
have been reported to lessen in AD. 
 
Table 2: Effect of RRLE on the deposition of Aβ in mice hippocampus 
 
Group Number Amyloid beta deposits in CA1 (% of 3xTg) 
Amyloid beta deposits in CA3 
(% of 3xTg) 
control 8 51.5 ± 2.2 71.7 ± 1.5 
3xTg 8 103.7 ± 3.4** 102.8 ± 2.3** 
RRLE-L 8 92.3 ± 2.5 89.2 ± 2.1 
RRLE-H 8 75.8 ± 2.1# 77.4 ± 1.7# 
Aβ deposits in the hippocampal CA3 region that were detected with immunohistochemical 
staining by using an anti-Aβ antibody. Quantification of Aβ deposits in the hippocampus CA1 
and CA3. The data are shown as the mean ± SEM. **p < 0.01, compared with control mice. #p < 
0.05 compared with 3xTg group (one-way ANOVA and Tukey's post-hoc tests) 
 
     Table 3: Effect of RRLE on BDNF and TrkB expression in mice hippocampus 
 
Group Number TrkB/beta action ratio BDNF/beta action ratio 
Control 8 1.3 ± 0.3 1.2 ± 0.3 
3xTg 8 0.7 ± 0.1* 0.8 ± 0.2* 
RRLE-L 8 0.9 ± 0.3 0.9 ± 0.2 
RRLE-H 8 1.1 ± 0.2# 1.4 ± 0.2# 
Superscript notations indicate significant differences at *p < 0.05, compared to control 
mice, #p < 0.05, compared to untreated mice (one-way ANOVA and Tukey's post-hoc 
tests) 
 
It was hypothesized that BDNF and its receptor 
may be involved in the protective role of RRLE 
against memory impairment. Results of the 
present study have demonstrated that RRLE 
intake significantly increases the expression of 
BDNF and its main receptor TrkB, in the brain, 
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which is in agreement with our hypothesis. There 
is evidence to support our results. It has been 
demonstrated that BDNF and TrkB, are capable 
of protecting against memory impairment and 
regulate neurogenesis in the hippocampus of 
AD. A recent study also supports the role of 
BDNF signaling through TrkB in the 
pathophysiology and cognitive and its receptor 




The findings of this study reveal that RRLE 
attenuates learning and memory deficits in 3xTg-
AD mice, and thus, the plant material can 
potentially be developed as an alternative 
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